Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Formycon Delay Pushes Back Coherus’ Ranibizumab

FDA Requests Additional Data On Lucentis Rival

Executive Summary

Formycon and Bioeq’s US filing for a biosimilar ranibizumab rival to Lucentis has been delayed after the FDA requested further data following a manufacturing change. Rights to the biosimilar have been licensed exclusively to Coherus in the US.

You may also be interested in...



Ranibizumab SPC Cut By Nearly Two Years In UK

A ruling by the High Court has cut almost two years from UK SPC protection for Roche's Lucentis ranibizumab brand, potentially offering biosimilar competitors the change to jump into the market early.

Coherus Content With Dual Pipeline Strategy

Coherus BioSciences sees value in having both wholly-owned and in-licensed biosimilar assets, as the firm gears up to have a portfolio of at least six products within five years.

Keeping Track: Seqirus Pandemic Flu Vaccine Approved; Trevena Resubmits Oliceridine

The latest drug development news and highlights from our US FDA Performance Tracker.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149586

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel